Orexo AB (publ) (STO: ORX)
Sweden
· Delayed Price · Currency is SEK
13.80
+0.92 (7.14%)
Dec 2, 2024, 3:14 PM CET
Orexo AB Revenue
Orexo AB had revenue of 136.50M SEK in the quarter ending September 30, 2024, a decrease of -12.56%. This brings the company's revenue in the last twelve months to 595.70M, down -5.26% year-over-year. In the year 2023, Orexo AB had annual revenue of 638.80M with 2.32% growth.
Revenue (ttm)
595.70M
Revenue Growth
-5.26%
P/S Ratio
0.84
Revenue / Employee
5.27M
Employees
116
Market Cap
500.33M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 638.80M | 14.50M | 2.32% |
Dec 31, 2022 | 624.30M | 59.30M | 10.50% |
Dec 31, 2021 | 565.00M | -98.60M | -14.86% |
Dec 31, 2020 | 663.60M | -181.20M | -21.45% |
Dec 31, 2019 | 844.80M | 61.70M | 7.88% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca PLC | 519.35B |
Swedish Orphan Biovitrum AB (publ) | 25.44B |
Sectra AB (publ) | 3.17B |
Getinge AB (publ) | 33.59B |
Camurus AB (publ) | 1.69B |
Vitrolife AB (publ) | 3.56B |
Medicover AB (publ) | 22.60B |
Elekta AB (publ) | 17.72B |
Orexo AB News
- 5 weeks ago - Orexo initiates new study of OX640 in participants with allergic rhinitis - PRNewsWire
- 5 weeks ago - Orexo AB reports Q3 results - Seeking Alpha
- 2 months ago - Orexo´s Nomination Committee for the Annual General Meeting 2025 - PRNewsWire
- 3 months ago - Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024 - PRNewsWire
- 4 months ago - Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose - PRNewsWire
- 5 months ago - Orexo AB´s sustainability work ranked among top 5% by EcoVadis - PRNewsWire
- 5 months ago - Orexo: invitation to presentation of the Q2 2024 Interim Report - PRNewsWire
- 7 months ago - Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm - PRNewsWire